Related references
Note: Only part of the references are listed.Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases A Phase 0/I Study
Lin Qiu et al.
CLINICAL NUCLEAR MEDICINE (2023)
Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases
Qixin Wang et al.
MOLECULAR PHARMACEUTICS (2023)
Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics
Anna Eshghi et al.
CLINICAL NUCLEAR MEDICINE (2022)
Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA
Yingwei Wang et al.
FRONTIERS IN ONCOLOGY (2022)
Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases
Rene Fernandez et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System
Joseph Kabunda et al.
CLINICAL NUCLEAR MEDICINE (2021)
Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Ashutosh Dashu et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Preliminary results of biodistribution and dosimetric analysis of [68Ga] Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases
Ambreen Khawar et al.
ANNALS OF NUCLEAR MEDICINE (2019)
Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results
Ambreen Khawar et al.
EJNMMI RESEARCH (2019)
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
Daria Handkiewicz-Junak et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Which bisphosphonate to treat bone metastases?
Luis Costa
LANCET ONCOLOGY (2014)
Managing bone metastases and reducing skeletal related events in prostate cancer
Benjamin A. Gartrell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)